Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RMAD1
- Development stage
- Preclinical
- Lead developer
- Remedii
- Modality
- Vaccines & Immunotherapeutics, Peptides
01
Overview
RMAD1 is a preclinical peptide-based cancer vaccine candidate developed by Remedii. It utilizes the company's proprietary Cell Penetrating Peptide (CPP) and Intracellular Drug Delivery Technology (IDDT) platform. The drug is designed as a peptide-antigen conjugate, where the CPP component facilitates the intracellular delivery of specific cancer antigens. By delivering these antigens directly into cells, RMAD1 aims to enhance the presentation of tumor-associated antigens to the immune system, thereby eliciting a robust anti-tumor immune response. The candidate is currently in the preclinical stage of development for the treatment of various cancers.
Beyond the preview
Go deeper on RMAD1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RMAD1.